Cancer Biology and Medicine
短名 | Cancer Biol Med |
Journal Impact | 5.66 |
国际分区 | ONCOLOGY(Q1) |
期刊索引 | SCI Q2中科院 2 区中国科学引文数据库中国科技核心期刊目录 |
ISSN | 2095-3941 |
h-index | 62 |
国内分区 | 医学(2区)医学医学研究与实验(3区)医学肿瘤学(3区) |
CANCER BIOLOGY & MEDICINE (ISSN 2095-3941) 是中国抗癌协会 (CACA) 的同行评审开放获取期刊,CACA 是中国领先的肿瘤学专业学会。该杂志季刊提供有关癌症生物学基础、癌症微环境、转化癌症研究以及临床癌症研究各个方面的创新和重要信息。该杂志还发表了关于中国本土癌症类型的重要观点。
期刊主页投稿网址涉及主题 | 医学生物遗传学内科学癌症化学生物化学癌症研究病理肿瘤科基因免疫学外科物理放射科数学细胞生物学 |
出版信息 | 出版商: Cancer Biology and Medicine,出版周期: Quarterly,期刊类型: journal |
基本数据 | 创刊年份: 2012,原创研究文献占比: 58.14%,自引率:14.30%, Gold OA占比: 93.06% |
平均审稿周期 | 网友分享经验:12 Weeks |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2– advanced breast cancer
2024-9-11
Weight gain after 35 years of age is associated with increased breast cancer risk: findings from a large prospective cohort study
2024-8-27
The current role of dendritic cells in the progression and treatment of colorectal cancer
2024-8-22
Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine
2024-8-9
Global, regional, and national burden of early-onset gastric cancer
2024-8-7
Esophageal cancer global burden profiles, trends, and contributors
2024-7-26
Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study
2024-7-26
Impact of cancer diagnosis on life expectancy by area-level socioeconomic groups in New South Wales, Australia: a population-based study
2024-7-22
Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei
2024-7-18
Attributable liver cancer deaths and disability-adjusted life years in China and worldwide: profiles and changing trends
2024-7-16
Epigenetic regulators as the foundation for molecular classification of colorectal cancer
2024-7-16
Multiple myeloma survival in New South Wales, Australia, by treatment era to 2020
2024-7-11
The role of reactive oxygen species in gastric cancer
2024-7-9
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis
2024-7-1
Modeling human gastric cancers in immunocompetent mice
2024-6-28
MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB
2024-6-27
Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants
2024-6-26
Unraveling the nexus between cellular senescence and malignant transformation: a paradigm shift in cancer research
2024-6-25
Research progress in tumor angiogenesis and drug resistance in breast cancer
2024-6-25
Amplifying colorectal cancer progression: impact of a PDIA4/SP1 positive feedback loop by circPDIA4 sponging miR-9-5p
2024-6-21
Effectiveness of colorectal cancer screening integrating non-genetic and genetic risk: a prospective study based on UK Biobank data
2024-6-20
Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells
2024-5-31
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial
2024-5-29
Immune checkpoint inhibitors: breakthroughs in cancer treatment
2024-5-24
Roles of cancer-associated fibroblast functional heterogeneity in shaping the lymphatic metastatic landscape: new insights and therapeutic strategies
2024-5-22
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer
2024-5-16
Advances in MET tyrosine kinase inhibitors in gastric cancer
2024-5-10
Development of small molecule drugs targeting immune checkpoints
2024-5-9
Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition
2024-5-6
Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma
2024-5-6
Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer
2024-4-9
A retrospective analysis of mature T- and NK-cell lymphomas
2024-3-27
Erratum to Treatment strategies for patients with HER2-positive gastric cancer
2024-3-27
Reducing the global cancer burden with gastrointestinal screening: China’s 30 years practice
2024-3-27
Decreased LDHB expression in breast tumor cells causes NK cell activation and promotes tumor progression
2024-3-25
Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial
2024-3-4
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies
2024-2-29
Influence of sex on outcomes of liver transplantation for hepatocellular carcinoma: a multicenter cohort study in China
2024-2-28
Current and future trends in whole genome sequencing in cancer
2024-2-15
Nodal peripheral T-cell lymphomas in the new classification systems
2024-2-5
Insight into the evolution of breast cancer driven by genetic alterations
2024-2-5
Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer
2024-2-5
The Warburg effect drives dedifferentiation through epigenetic reprogramming
2024-2-5
Road of no return — loss of TP53 paves a defined evolution path from gastric preneoplasia-to-cancer
2024-2-5
Treatment strategies for patients with HER2-positive gastric cancer
2024-2-5
Diagnosis of malnutrition in cancer patients
2024-2-5
Drug clinical trials on high-grade gliomas: challenges and hopes
2024-2-5
Hot issues in triple-negative breast cancer
2024-2-5
Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer
2024-2-5
Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?
2024-2-5
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远